Halozyme Therapeutics HALO Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total revenue?
- Halozyme Therapeutics (HALO) reported total revenue of $376.71M in Q1 2026.
- How has Halozyme Therapeutics's total revenue changed year-over-year?
- Halozyme Therapeutics's total revenue increased by 42.2% year-over-year, from $264.86M to $376.71M.
- What is the long-term trend for Halozyme Therapeutics's total revenue?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's total revenue has grown at a 33.2% compound annual growth rate (CAGR), from $443.31M to $1.4B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities.
- How do you interpret total revenue?
- An increase indicates growing market share or successful pricing strategies, while a decrease may signal weakening demand or competitive pressure.
- How does total revenue compare across companies?
- Standardized across all public companies; peers in biotech typically show high revenue growth correlated with product launches.